{"filings":[{"id":1389916,"accession_number":"0001773751-26-000146","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2026-07-01T21:02:46+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Hims & Hers enters $400M receivables purchase facility with JPMorgan, 364-day term","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Receivables Purchase Agreement allows sale of eligible receivables up to $400M outstanding.","Facility is uncommitted; JPMorgan may decline any purchase in its sole discretion.","Initial term of 364 days, extendable by mutual written agreement for up to one year each time.","Hims & Hers provides a performance undertaking for the sellers, but not a collectibility guarantee.","Credit Agreement amended to permit the RPA and add a $400M indebtedness basket."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1058676,"accession_number":"0001773751-26-000096","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2026-06-15T21:02:49+00:00","items":["5.07"],"status":"ready","headline":"Hims & Hers annual meeting results: all nominees and proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting held June 11, 2026; all nine director nominees elected with over 1.5B votes each.","Ratification of KPMG as independent auditor for FY 2026: 1,591,246,881 for, 516,386 against.","Advisory vote on executive compensation approved: 1,506,477,171 for, 11,181,420 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":787001,"accession_number":"0001773751-26-000091","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2026-06-02T10:02:26+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Hims & Hers completes acquisition of Eucalyptus; reaffirms 2030 targets of $6.5B revenue","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed, making Hims & Hers the world's largest consumer health platform.","Eucalyptus brings 850K+ customers and presence in Australia, Canada, Germany, Japan, UK.","Company reaffirms long-term targets: $6.5B revenue and $1.3B Adjusted EBITDA by 2030.","Tim Doyle, former Eucalyptus CEO, appointed SVP International at Hims & Hers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":584082,"accession_number":"0001193125-26-234847","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2026-05-21T21:05:00+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Hims & Hers issues $402.5M of 0% convertible notes due 2032; enters capped calls","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $402.5M aggregate principal of 0.00% Convertible Senior Notes due June 1, 2032.","Initial conversion rate of 33.8590 shares per $1,000 principal; conversion price ~$29.53 per share.","Capped call transactions cost $36.7M, cap price ~$50.15 per share, to reduce dilution on conversion.","Notes redeemable on/after June 6, 2029 if stock exceeds 130% of conversion price for specified periods.","Offering made to QIBs under Rule 144A; potential maximum 18,057,397 shares issuable upon conversion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":508996,"accession_number":"0001193125-26-229749","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2026-05-19T12:17:31+00:00","items":["8.01","9.01"],"status":"ready","headline":"Hims & Hers prices $350M 0.00% convertible notes due 2032; funds Eucalyptus acquisition & AI","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Offering upsized from $300M to $350M; initial purchasers can buy additional $52.5M.","Notes mature June 1, 2032; zero coupon; initial conversion price ~$29.53/share (32.5% premium over $22.29 close).","Net proceeds ~$338.5M; $32M for capped call transactions; remainder for international expansion, including Eucalyptus acquisition, AI, and infrastructure.","Capped call transactions reduce dilution, cap price initially ~$50.15/share.","Settlement expected May 21, 2026; Eucalyptus acquisition expected mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":13002,"accession_number":"0001773751-26-000074","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2026-05-11T20:08:27+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hims & Hers Q1 net loss $92.1M; revenue $608M (+4% YoY); raises FY2026 guidance to $2.8B-$3.0B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $608.1M (+4% YoY); net loss $92.1M vs net income $49.5M in Q1 2025.","Adjusted EBITDA $44.3M vs $91.1M; gross margin fell to 65% from 73%.","Subscribers 2.584M (+9% YoY); monthly revenue per subscriber $80 (-6%).","FY2026 revenue guidance raised to $2.8B–$3.0B; Adjusted EBITDA guidance $275M–$350M.","Proposed acquisition of Eucalyptus expected mid-2026; not included in guidance."],"consensus_eps_estimate":0.0442,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":608104000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108333,"accession_number":"0001773751-26-000033","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Hims & Hers partners with Novo Nordisk, shifts US weight loss strategy to FDA-approved GLP-1s","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration with Novo Nordisk to offer Ozempic and Wegovy on platform starting March 2026.","Will no longer advertise compounded GLP-1s; limited compounding only for clinical necessity.","Novo Nordisk dismisses its lawsuit against Hims & Hers without prejudice.","Existing patients can transition to FDA-approved GLP-1s when clinically appropriate.","CEO Dudum: partnership enables scaled distribution of innovations for affordable access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108332,"accession_number":"0001773751-26-000019","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hims & Hers FY2025 revenue up 59% to $2.35B, adj. EBITDA $318M; guides FY2026 rev $2.7-2.9B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.35B (+59% YoY); net income $128M; adj. EBITDA $318M vs $177M prior year.","Q4 revenue $618M (+28% YoY); net income $20.6M; adj. EBITDA $66.3M.","Subscribers at 2.5M (+13% YoY); monthly revenue per avg subscriber $83 (+28% YoY).","FY2026 guidance: revenue $2.7-2.9B, adj. EBITDA $300-375M; excludes potential Eucalyptus acquisition.","Non-GLP-1 revenue majority; compounded semaglutide access assumed in guidance."],"consensus_eps_estimate":0.0467,"consensus_eps_actual":0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":2347637000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108331,"accession_number":"0001773751-26-000010","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Hims & Hers acquires Eucalyptus for up to $1.15B, expanding globally","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Transaction valued up to $1.15B: ~$240M cash upfront, ~$710M deferred over 18 months, up to ~$200M earnouts.","Eucalyptus has ARR >$450M, triple-digit YoY growth in 2025, and served >775,000 customers.","Tim Doyle, Eucalyptus CEO, to become SVP of International at Hims & Hers post-close.","Acquisition expected to close mid-2026, subject to regulatory approvals and customary conditions.","Hims & Hers to finance with existing cash and US operating cash flows; option to settle payments in stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124780,"accession_number":"0001773751-25-000362","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Hims & Hers Health authorizes new $250M share repurchase program; prior $100M fully used","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["New $250M share repurchase program authorized by Board on Nov 13, 2025, expiring Nov 11, 2028.","From Oct 1 to Nov 7, 2025, repurchased 1,334,572 shares for $55.5M, exhausting prior $100M program.","Repurchases may be made via open market, private negotiations, or Rule 10b5-1 plans; program may be suspended or discontinued.","New authorization increases buyback capacity by 2.5x compared to the prior $100M program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124779,"accession_number":"0001773751-25-000352","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hims & Hers Q3 revenue $599M (+49% YoY), Adj. EBITDA $78.4M; narrows FY25 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $599M (+49% YoY), net income $15.8M (prior-year $75.6M included $60.8M tax benefit)","Adj. EBITDA $78.4M (+53% YoY); subscribers 2.47M (+21% YoY); monthly online revenue per subscriber $80 (+19% YoY)","Gross margin 74% vs 79% YoY, hit by shorter shipping cadences for weight-loss offerings","FY25 revenue guidance narrowed to $2.34-2.36B, Adj. EBITDA guidance $307-317M","Entering testosterone, menopause care; discussions with Novo Nordisk for Wegovy; GRAIL investment"],"consensus_eps_estimate":0.1063,"consensus_eps_actual":0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":1729819000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124778,"accession_number":"0001773751-25-000331","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2025-10-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hims & Hers COO Nader Kabbani transitions to advisory role; Mike Chi promoted to COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nader Kabbani steps into advisory role effective Nov 2, 2025, through July 2026.","Mike Chi, formerly Chief Commercial Officer, appointed COO effective Nov 2, 2025.","Chi will oversee operations, marketing, product, and commercial functions in consolidated role.","Chi joined Hims & Hers in April 2021; prior roles include CMO at Zola and VP at INTERMIX.","Compensation Committee will review potential adjustments to Chi's pay for his expanded responsibilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141478,"accession_number":"0001773751-25-000318","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"No material event: Hims & Hers lists investor communication channels","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company updates list of official investor communication channels including websites and social media.","CEO Andrew Dudum's personal X account added to disclosure list.","No financial data, guidance, or operational updates released in this filing.","Investors directed to hims.com, forhers.com, LinkedIn, and X for future material announcements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141477,"accession_number":"0001773751-25-000291","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Hims & Hers signs 15-year lease for 352,012 sq ft Ohio facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease for 352,012 sq ft in New Albany, OH, for office, R&D, lab, manufacturing, and pharmaceutical dispensing.","Initial term 15 years with two 5-year renewal options; base rent starts at ~$5.98M annually ($498,684/month).","Rent abated for first 7 months, then partial abatement of $262,838/month for 5 months post-commencement.","Rent escalates ~3.25% annually; security deposit of $5.98M via letter of credit; parent company guarantees obligations.","Occupancy expected April 2026; facility to support Hims & Hers' pharmaceutical dispensing operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141476,"accession_number":"0001773751-25-000248","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Hims & Hers Q2 rev $545M (+73%), net income $42.5M, reaffirms FY25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $544.8M (+73% YoY); net income $42.5M (vs $13.3M); Adj EBITDA $82.2M (vs $39.3M).","Subscribers 2.44M (+31% YoY); monthly online revenue per subscriber $74 (+30% YoY).","Gross margin 76% (down ~500 bps YoY); free cash flow -$69.4M (vs +$47.6M prior year).","FY25 guidance reaffirmed: revenue $2.3-2.4B and Adj EBITDA $295-335M.","Acquired ZAVA Global (European digital health); expects $50M+ revenue from ZAVA in H2 at positive EBITDA."],"consensus_eps_estimate":0.1541,"consensus_eps_actual":0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":1130843000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159320,"accession_number":"0001773751-25-000211","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Hims & Hers shareholders elect directors, ratify KPMG, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 director nominees elected; top vote-getter Kare Shcultz with 1.55B For; broker non-votes 55.9M shares.","KPMG LLP ratified as independent auditor for FY2025: 1.61B For, 0.16M Against, 0.48M Abstentions.","Advisory say-on-pay resolution approved: 1.53B For, 26.5M Against, 0.31M Abstentions; 55.9M broker non-votes.","Total shares outstanding at record date: 215.3M Class A common and 8.4M Class V common (175 votes per Class V share)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159319,"accession_number":"0001193125-25-118948","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Hims & Hers issues $1B 0% convertible notes due 2030; enters capped call transactions to reduce dilution","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1.0B aggregate principal of 0.00% Convertible Senior Notes due 2030 issued May 13, 2025.","Initial conversion price ~$70.67 per share; conversion rate 14.1493 shares per $1,000 note.","Capped call transactions with initial cap price $89.95/share cost $47.8M to offset dilution on conversion.","Notes mature May 15, 2030; redeemable after May 19, 2028 if stock exceeds 130% of conversion price.","Initial purchasers' $130M option exercised in full on May 9, 2025, bringing total to $1.0B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159318,"accession_number":"0001193125-25-116439","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Hims & Hers prices $870M 0.00% convertible notes due 2030 for global expansion and AI investment","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $450M offering upsized to $870M; initial purchasers option for additional $130M.","Zero-coupon notes due 2030; initial conversion price ~$70.67/share (37.5% premium over $51.40 close).","Net proceeds est. $842.7M ($968.8M if full exercise); ~$41.6M for capped call transactions.","Proceeds for global expansion (organic + M&A), AI/data platform; no material acquisition agreements yet.","New CTO Mo Elshenawy leading tech team to develop AI tools and personalized treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159317,"accession_number":"0001773751-25-000152","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hims & Hers Q1 revenue $586M (+111% YoY), net income $49.5M, raises EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $586M (+111% YoY); net income $49.5M (up 345% YoY); Adj. EBITDA $91.1M (up 182% YoY).","Subscribers 2.4M (+38% YoY); monthly online rev per sub $84 (+53% YoY).","Affirms FY2025 revenue guidance $2.3-$2.4B; raises Adj. EBITDA outlook to $295-$335M.","Introduced 2030 targets of at least $6.5B revenue and $1.3B Adj. EBITDA.","Gross margin 73% (down 900bps YoY) on GLP-1 mix; partnered with Novo Nordisk for Wegovy access."],"consensus_eps_estimate":null,"consensus_eps_actual":0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":586010000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159316,"accession_number":"0001773751-25-000128","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hims & Hers COO Melissa Baird to step down, transition to advisory role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Baird will remain as COO until successor is identified and fully up to speed.","She intends to move into an advisory role under a long-term agreement post-transition.","Effective date of departure not yet determined; announcement made April 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177734,"accession_number":"0001773751-25-000059","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hims & Hers FY2024 revenue $1.48B (+69% YoY); net income $126M vs loss; guides FY2025 rev $2.3-2.4B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.48B for FY2024, up 69% YoY; Q4 revenue $481M, up 95% YoY.","Net income $126M for FY2024 vs net loss $23.5M FY2023; Adjusted EBITDA $177M.","Subscribers reached 2.2M, up 45% YoY; Monthly Online Revenue per Avg Subscriber $64.","FY2025 revenue guidance $2.3-2.4B; Adjusted EBITDA $270-320M.","Q4 gross margin 77% vs 83% prior year; weight loss GLP-1 offering drives acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":1476514000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194443,"accession_number":"0001773751-24-000371","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hims & Hers appoints Deb Autor to board; board expands to ten","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased from 9 to 10; Deb Autor appointed effective Nov 15, 2024.","Autor will serve until 2025 annual meeting; determined independent under NYSE rules.","She enters a one-year consulting agreement with $100,000 fee; standard director comp also applies.","Autor appointed to the Risk Committee along with Christopher Payne, Anja Manuel, Kåre Schultz, and David Wells."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194442,"accession_number":"0001773751-24-000337","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hims & Hers Q3 rev $401.6M (+77% YoY), net income $75.6M, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024: Revenue $401.6M (+77% YoY), net income $75.6M (vs -$7.6M), Adj EBITDA $51.1M.","Subscribers 2.0M (+44% YoY); over 1M using personalized solutions; ex-GLP-1 sub growth 40% YoY.","FY 2024 guidance raised: Revenue $1.460-1.465B, Adj EBITDA $173-178M.","Weight loss offering: oral GLP-1 $100M annual run rate; 80K reports of supply shortage; planning liraglutide in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":995375000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210766,"accession_number":"0001104659-24-098228","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Hims & Hers closes MedisourceRx acquisition; registers 976K shares for resale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acquisition of Seaview Enterprises LLC (MedisourceRx) closed on September 5, 2024.","976,341 shares of Class A common stock issued to Nivagen Pharmaceuticals as part of consideration.","Prospectus supplement filed on September 9, 2024 to register resale of those shares.","Purchase agreement was originally entered on July 5, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210765,"accession_number":"0001773751-24-000246","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hims & Hers Q2 revenue $315.6M (+52% YoY), turns profitable; raises FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $315.6M, up 52% YoY; subscribers 1.9M (+43% YoY).","Net income $13.3M vs net loss $7.2M YoY; adjusted EBITDA $39.3M (+270% YoY).","Raises FY2024 revenue guidance to $1.37-$1.40B; adjusted EBITDA guidance $140-$155M.","Announced up to $100M share repurchase program over three years."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":593819000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210764,"accession_number":"0001773751-24-000230","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hims & Hers Health appoints Kåre Schultz to board, effective July 16, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased from 8 to 9 to accommodate the newly created vacancy.","Kåre Schultz, age 63, is independent under NYSE and SEC standards.","Schultz will serve until the 2025 annual meeting of stockholders.","He has not yet been assigned to any board committees.","Compensation will follow the standard director compensation plan disclosed in the April 2024 proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229169,"accession_number":"0001773751-24-000185","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Hims & Hers stockholders elect all eight directors and ratify KPMG at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected with >97% of votes cast; broker non-votes of 39M shares.","KPMG ratified as independent auditor for FY2024 with 1.598B votes for, 182K against.","Advisory say-on-pay proposal passed with ~97% support (1.517B for, 42M against).","Total shares outstanding: 206.3M Class A and 8.4M Class V (each Class V share carries 175 votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229165,"accession_number":"0001773751-24-000164","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K/A","filed_at":"2024-06-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hims & Hers appoints Anja Manuel to audit and risk committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Anja Manuel added to audit and risk committees effective June 6, 2024.","Original election to the Board was announced April 24, 2024.","No other changes to board committee composition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229168,"accession_number":"0001773751-24-000130","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hims & Hers Q1 2024 revenue $278.2M (+46% YoY), net income $11.1M, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $278.2M, up 46% YoY; net income $11.1M vs loss of $10.1M a year ago.","Subscribers reached 1.7M, up 41% YoY, with a record 172k net additions.","Adjusted EBITDA $32.3M, up 434% YoY from $6.1M; gross margin improved to 82%.","FY2024 revenue guidance raised to $1.20-1.23B, Adjusted EBITDA to $120-135M, exceeding prior 2025 targets.","Over 35% of subscribers now on personalized solutions; marketing spend leverage improving."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":278171000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229167,"accession_number":"0001773751-24-000114","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hims & Hers appoints Anja Manuel to board, expanding to 11 directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 10 to 11 directors; Anja Manuel appointed effective April 24, 2024.","Ms. Manuel is independent under NYSE and SEC rules; no committee assignments yet.","She will receive standard director compensation per proxy filed April 26, 2024.","No family relationships or reportable transactions exist with current officers or directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229164,"accession_number":"0001773751-24-000112","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K/A","filed_at":"2024-04-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hims & Hers appoints Christopher Payne to compensation and risk committees","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Christopher Payne was elected to the Board effective March 30, 2024.","On April 23, 2024, the Board appointed him to the compensation and risk committees, effective June 6, 2024.","This amendment to the prior 8-K reports the committee assignments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229166,"accession_number":"0001773751-24-000093","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hims & Hers appoints Christopher Payne to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 9 to 10; Christopher Payne, 55, appointed effective March 30, 2024.","Payne deemed independent under NYSE and SEC standards; no committee assignments yet.","Initial RSU award valued at $400,000 under director compensation program; standard indemnification agreement entered.","No arrangements or family relationships with directors/officers; no transactions requiring disclosure under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247759,"accession_number":"0001773751-24-000023","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hims & Hers FY2023 revenue $872M (+65% YoY); Q4 net income $1.2M; guides FY2024 rev $1.17-1.20B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 revenue $872.0M, up 65% YoY; net loss improved to $(23.5)M from $(65.7)M.","Q4 2023 revenue $246.6M (+47% YoY); first net income quarter of $1.2M vs $(10.9)M loss.","Adjusted EBITDA Q4 $20.6M vs $3.9M; FY2023 Adj. EBITDA $49.5M vs $(15.8M) loss.","Subscribers reached 1.54M, up 48% YoY; monthly online revenue per subscriber $53.","Guides FY2024 revenue $1.17B-$1.20B; Adj. EBITDA $100M-$120M, beating 2025 target early."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":872000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265194,"accession_number":"0001773751-23-000276","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hims & Hers Q3 revenue $226.7M (+57% YoY), adjusted EBITDA $12.3M; raises FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $226.7M for Q3 2023, up 57% YoY from $144.8M; net loss narrowed to $7.6M from $18.8M.","Adjusted EBITDA turned positive at $12.3M vs. ($6.1M) in prior year; gross margin improved to 83% from 79%.","Subscribers reached 1.4M, up 56% YoY; monthly online revenue per subscriber $54 vs. $56.","Raised full year 2023 revenue guidance to $868M-$873M and Adjusted EBITDA to $43M-$46M.","Over 80% of orders fulfilled via affiliated facilities; AI-based MedMatch service introduced to aid personalized care."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":625381000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282395,"accession_number":"0001773751-23-000204","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hims & Hers Q2 revenue up 83% to $207.9M; raises FY 2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $207.9M, up 83% YoY; net loss narrowed to $7.2M from $19.7M.","Adjusted EBITDA turned positive at $10.6M versus -$7.5M in Q2 2022.","Subscribers grew 74% to 1.3M; monthly online revenue per subscriber $53.","Raised FY 2023 revenue guidance to $830-850M and Adjusted EBITDA to $35-40M.","Expanded into Cardiovascular Health and Weight Management categories."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":398682000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301597,"accession_number":"0001773751-23-000155","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"All director nominees elected, KPMG ratified, say-on-pay approved at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected with over 1.5 billion votes in favor each; no opposition to any.","Ratification of KPMG as independent auditor for FY2023 passed with 1.57B for, 785K against.","Advisory vote on executive compensation approved with 1.53B for, 16.4M against, 436K abstentions.","Meeting held June 1, 2023; record date April 14, 2023; Class V shares carry 175 votes each."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301596,"accession_number":"0001773751-23-000123","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hims & Hers Q1 revenue up 88% to $190.8M; raises FY2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $190.8M (+88% YoY); net loss narrowed to $10.1M from $16.3M; adj. EBITDA $6.1M vs -$6.1M.","Subscribers 1.2M (+87% YoY); monthly online revenue per subscriber $55 (+6%); AOV $90 (+15%).","Gross margin improved to 80% from 74%.","Raises FY2023 revenue guidance to $810M-$830M; adj. EBITDA guidance to $25M-$30M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":190770000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321373,"accession_number":"0001773751-23-000027","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hims & Hers Q4 revenue $167.2M (+97% YoY); achieves first positive adjusted EBITDA of $3.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $167.2M, up 97% YoY; full year revenue $526.9M, up 94% YoY.","Q4 net loss narrowed to $10.9M from $31.2M; adjusted EBITDA positive $3.9M (vs -$7.1M).","Subscribers surpassed 1M (1.04M), up 88% YoY; monthly online revenue per subscriber $55.","FY2023 guidance: revenue $735-755M, adjusted EBITDA $20-30M.","Introduced 2025 targets: at least $1.2B revenue and $100M adjusted EBITDA."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":526916000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321372,"accession_number":"0001773751-23-000015","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hims & Hers appoints Christiane Pendarvis to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 10 to 11 directors; Pendarvis fills newly created vacancy effective Feb 16, 2023.","Pendarvis, 52, deemed independent under NYSE and SEC rules; no committee assignment yet.","She will serve until the 2023 annual meeting; compensation per standard director program.","No family relationships with any director or executive officer; no transactions requiring disclosure.","Pendarvis will enter the company's standard indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339495,"accession_number":"0001773751-22-000226","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hims & Hers Q3 revenue $144.8M (+95% YoY); raises FY 2022 guidance; expects Q4 Adj. EBITDA profitability","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $144.8M, up 95% YoY; net loss $(18.8)M vs $(15.9)M a year ago.","Adjusted EBITDA improved to $(6.1)M from $(9.8)M; expects Q4 2022 Adjusted EBITDA profitability.","Subscriptions reached 991,000 (+80% YoY); Q3 net new subscriptions all-time high >170,000.","Raises FY 2022 revenue guidance to $519-522M; Adjusted EBITDA guidance to $(20)-$(18)M.","Gross margin expanded to 79% from 74% YoY; net loss improved on adjusted basis."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":359713000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356859,"accession_number":"0001773751-22-000162","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hims & Hers Q2 revenue $113.6M (+87% YoY); raises FY22 revenue guidance to $470-485M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $113.6M, up 87% YoY; net loss $(19.7M) vs $(9.2M) prior year.","Quarterly net new subscriptions >100k, total subscriptions 817k, up 80% YoY.","Raises FY22 revenue guidance to $470-485M and Adjusted EBITDA guidance to $(27)M-$(20)M.","Gross margin 77% (78% prior year); expects Adjusted EBITDA profitability within next four quarters.","Launched Hers mobile app and 6 new Wellness Essentials supplements for women."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":214877000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375339,"accession_number":"0001193125-22-170297","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2022-06-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Hims & Hers stockholders approve all proposals at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected ten directors, including CEO Andrew Dudum, with over 1.5B votes each; broker non-votes ~41.4M.","Ratified KPMG as independent auditor for FY2022: 1.57B for, 656,788 against, 617,606 abstentions.","Advisory say-on-pay approved: 1.53B for, 3.2M against, 725,386 abstentions.","Stockholders chose one-year frequency for future advisory votes on executive compensation.","Board determined to hold annual say-on-pay votes until next frequency vote expected at 2028 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375338,"accession_number":"0001773751-22-000116","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hims & Hers Q1 revenue $101.3M (+94% YoY); raises FY2022 guidance to $410-425M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $101.3M, up 94% YoY; net loss improved to $(16.3)M from $(51.4)M.","Subscriptions 710,000 (+82% YoY); net orders 1,207,000 (+76% YoY).","Adjusted EBITDA loss narrowed to $(6.1)M from $(8.6)M; gross margin 74% vs 77%.","Raises FY2022 revenue guidance to $410-425M; maintains adjusted EBITDA guidance $(30-20)M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":101314000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393718,"accession_number":"0001773751-22-000106","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2022-03-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Hims & Hers conducts non-deal roadshow with investor deck; no material updates","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Management held non-deal roadshow meetings with investors on March 29-30, 2022.","Investor presentation provided covers company strategy and operations; no new financial data disclosed.","No earnings, guidance, or material corporate events announced in the filing or exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393717,"accession_number":"0001773751-22-000030","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2022-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hims & Hers Q4 revenue $84.7M (+104% YoY); FY2021 revenue $271.9M; guides FY2022 rev $365-380M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $84.7M (+104% YoY); net loss $(31.2)M vs $(5.2)M loss in Q4 2020.","Full year 2021 revenue $271.9M (+83% YoY); net loss $(107.7)M vs $(18.1)M.","Subscriptions at 609,000, up 95% YoY; gross margin 73% in Q4 vs 77% a year ago.","Provides Q1 and FY2022 guidance: FY2022 revenue $365-380M; Adj EBITDA $(30)M to $(20)M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":271878000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393716,"accession_number":"0001193125-22-028399","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2022-02-04T23:59:59+00:00","items":["8.01","2.01","9.01"],"status":"ready","headline":"Hims & Hers recasts 2020 & 2019 financials for reverse recapitalization","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Recast audited consolidated financial statements for years ended Dec 31, 2020 and 2019.","Reflects reverse recapitalization with Oaktree Acquisition Corp. closing Jan 20, 2021.","Share exchange ratio applied: 0.4530 shares of Class A common stock per Hims share.","No change to underlying operational results; only historical per-share and equity presentation.","Incorporates consent of independent auditor KPMG."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393715,"accession_number":"0001773751-22-000010","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2022-01-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hims & Hers appoints new CFO Oluyemi Okupe, adds Dr. Patrick Carroll to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Oluyemi Okupe as CFO effective Jan 24, 2022; previously CFO of Hipcamp, divisional CFO at Uber and Braintree.","Okupe receives $450K base salary, $350K signing bonus (conditional on 180 days service), and $7M equity grant (40% options, 60% RSUs).","Board expanded to 10 directors; Dr. Patrick Carroll (former CMO) appointed director effective Feb 1, 2022.","Dr. Carroll resigned as Chief Medical Officer effective Jan 31, 2022; will stand for election at 2022 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412248,"accession_number":"0001773751-21-000067","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2021-11-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hims & Hers CFO Spencer Lee resigns; Irene Becklund named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Spencer Lee resigned as CFO, principal financial officer and accounting officer effective Nov 15, 2021; previously disclosed plan.","Irene Becklund (company controller since June 2019) appointed interim principal financial officer and accounting officer.","Lee to support transition as consultant through Feb 28, 2022 at $15,000/month.","Becklund received 25,000 RSUs vesting quarterly over one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412247,"accession_number":"0001773751-21-000053","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hims & Hers Q3 2021 revenue up 79% YoY to $74.2M; raises FY2021 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $74.2M (+79% YoY); net loss -$15.9M vs -$5.9M prior year.","Ending subscriptions 551k (+95% YoY); AOV stable at $74.","Adjusted EBITDA -$9.8M vs -$1.6M prior year; gross margin 74% vs 76%.","Exceeded Q3 revenue guidance; raised full-year 2021 revenue outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":187179000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430952,"accession_number":"0001193125-21-266057","cik":1773751,"company_name":"Hims & Hers Health, Inc.","ticker":"HIMS","form_type":"8-K","filed_at":"2021-09-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Hims & Hers CFO Spencer Lee to step down; company reaffirms Q3 and FY 2021 guidance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Spencer Lee resigns, will lead six-month transition; resignation not due to any accounting disagreements.","Search for new CFO led by CEO Andrew Dudum and board member David Wells (former Netflix CFO).","Company reaffirms Q3 and full-year 2021 financial guidance previously provided on Aug. 11, 2021.","Lee joined in March 2019, helped with public transition, two acquisitions, and strong quarterly results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5835048822.081349,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-09-07T23:59:59+00:00|430952"}